Reunion Neuroscience, Inc., a clinical-stage biopharmaceutical company committed to revolutionizing the treatment of underserve ...
Company on track to report topline results early in the second quarter of 2026 Second planned Data and Safety Monitoring Board (DSMB) meeting evaluated all available ...
Running separate protocols for multiple investigational products and disease subpopulations slows development and duplicates infrastructure. There is growing interest in accelerating drug development ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback